疑似家族性与散发性特发性肺纤维化的临床病程:PROOF-Next登记研究
该研究基于比利时和卢森堡多中心前瞻性纵向观察性IPF登记(PROOF-Next),比较618例疑似家族性肺纤维化(FPF)与散发性IPF患者的特征和临床病程,其中76例(12%)符合FPF标准。FPF患者更年轻,吸烟包年数更低,但基线肺功能、进展中位时间及无移植生存相似,且抗纤维化治疗比例更高。结论提示FPF进展同样侵袭性,应早期转诊至专家中心。
要点
- FPF患者较sIPF更年轻(中位65 vs 72岁,p=0.0001),但疾病进展同样侵袭性。
- FPF与sIPF基线肺功能、进展中位时间和无移植生存相似。
- FPF患者抗纤维化治疗比例更高(87% vs 76%,p=0.047),建议早期转诊专家中心。
核心结论
- 疑似家族性肺纤维化患者虽更年轻且烟草暴露更少,但疾病进展与散发性IPF同样侵袭性。
- 结果支持将疑似家族性肺纤维化患者早期转诊至专家中心以优化管理。
研究设计与样本
- 比利时和卢森堡多中心前瞻性纵向观察性IPF登记研究(PROOF-Next)。
- 共纳入618例患者进行分析,其中76例(12%)符合疑似家族性肺纤维化标准。
主要发现
- FPF患者中位年龄65岁(范围43-87),显著低于sIPF的72岁(范围51-98),p=0.0001。
- 当前和既往吸烟者中,FPF包年数更低(20 vs 25,p=0.02)。
- FPF与sIPF基线肺功能检查相似,进展中位时间和无移植生存也相似。
- 87%的FPF和76%的sIPF患者接受抗纤维化治疗(p=0.047)。
- 少数患者完成基因检测,鉴定出10个端粒酶相关基因变异。
关键数值与推荐
- 疑似家族性肺纤维化定义为患者年龄小于50岁和/或至少有一名亲属患肺纤维化。
- FPF中位年龄65岁(范围43-87),sIPF中位年龄72岁(范围51-98),p=0.0001。
- 当前和既往吸烟者包年数FPF为20,sIPF为25,p=0.02。
- 抗纤维化治疗比例FPF为87%,sIPF为76%,p=0.047。
临床怎么用
- 对疑似家族性肺纤维化患者应早期转诊至专家中心。
- 即使患者年轻且烟草暴露少,也应认识到其疾病进展可能同样侵袭性。
局限性
- 基因检测仅在少数患者中进行。
- 疑似家族性肺纤维化的真实世界数据仍然稀少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Real-life data on suspected familial fibrosis, defined as the occurrence of the disease in a patient younger than 50 and/or having at least one relative affected by pulmonary fibrosis remain scarce. METHODS: The Belgian and Luxembourg IPF registry (PROOF-Next) is a multicentric prospective longitudinal and observational study set in Belgium and Luxembourg. We compared characteristics and clinical course of patients with suspected familial pulmonary fibrosis (FPF) and sporadic IPF. RESULTS: We included 618 patients in the analysis, of whom 76 (12%) fulfilled criteria for FPF. They were significantly younger than sIPF (median age (range) 65 (43-87), vs. 72 (51-98), p = 0.0001). Male gender proportion and smoking status did not differ between groups, but the number of pack-year among current and former smokers was lower in FPF (20 vs. 25, p = 0.02). Besides, 87% of FPF and 76% of sIPF were treated with antifibrotic (p = 0.047). Baseline pulmonary function tests were similar in both groups, as well as median time before progression and transplant-free survival. Finally, genetic testing, performed in a minority, led to the identification of 10 telomerase-related gene variants. CONCLUSION: Although younger and exposed to less tobacco, patients with FPF show an equally aggressive progression as observed in sporadic IPF patients. These results warrant early referral of FPF patients to expert centres for optimal management.
引用
- Froidure A, Bondue B, Dahlqvist C, et al. Clinical course of suspected familial and sporadic idiopathic pulmonary fibrosis: Data from the PROOF-Next registry. Respirology. 2023. PMID: 38123492. doi:10.1111/resp.14650
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。